NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Debt-to-Equity : 0.83 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is NovaBay Pharmaceuticals Debt-to-Equity?

NovaBay Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.63 Mil. NovaBay Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.11 Mil. NovaBay Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $3.31 Mil. NovaBay Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.83.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NovaBay Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

NBY' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.33 Med: 0.12 Max: 4.16
Current: 0.83

During the past 13 years, the highest Debt-to-Equity Ratio of NovaBay Pharmaceuticals was 4.16. The lowest was -0.33. And the median was 0.12.

NBY's Debt-to-Equity is ranked worse than
84.31% of 1071 companies
in the Biotechnology industry
Industry Median: 0.15 vs NBY: 0.83

NovaBay Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for NovaBay Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovaBay Pharmaceuticals Debt-to-Equity Chart

NovaBay Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

4.16

0.04

0.05

0.19

0.83

NovaBay Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.19	0.22	0.36	0.43	0.83

Competitive Comparison of NovaBay Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, NovaBay Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovaBay Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBay Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NovaBay Pharmaceuticals's Debt-to-Equity falls into.

NovaBay Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NovaBay Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.632	+	1.108)	/	3.314
	=	0.83

NovaBay Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.632	+	1.108)	/	3.314
	=	0.83

NovaBay Pharmaceuticals (AMEX:NBY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

NovaBay Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NovaBay Pharmaceuticals Inc (AMEX:NBY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

B9P:Germany

Address

2000 Powell Street, Suite 1150, Emeryville, CA, USA, 94608

Website

https://www.novabay.com

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

Executives

Tommy Law	officer: Interim CFO	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Jeffrey Kunin	officer: President, DERMAdoctor, LLC	4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Audrey Kunin	officer: Chief Product Officer	4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Justin Hall	officer: General Counsel	5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608
Yongxiang Zheng	director	NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316
Julie Garlikov	director	2420 17TH STREET, SUITE 220, DENVER CO 80202
Andrew D. Jones	officer: CFO and Treasurer	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Mijia Wu	director	SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA
Jian Ping Fu	10 percent owner	LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125
Wang Xu	officer: NEO - Sr Mgr and Controller	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Swan Sit	director	95 JACKSON STREET, NEWTON MA 02459
Yenyou Zheng	director	1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9
Xiaopei Wang	director	2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109
Jason Philip Raleigh	officer: Interim CFO and Treasurer	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Pioneer Pharma (hong Kong) Co Ltd	10 percent owner	FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000